Study of EndoBarrier Liner for Treatment of Type 2 Diabetes Study

Inclusion Criteria: * Subjects Age \> 18 years and ≤ 55 years * Male or Female * Subjects with Type 2 Diabetes who have been treated for ≤10 years and are on oral diabetic medications * Subjects with an HbA1C \> 7.5 and ≤ 10.0% * Subjects with a BMI \> 26 - \< 50 * Subjects willing to comply with study requirements * Subjects who have signed an informed consent form * Women who are post-menopausal, surgically sterile or on oral contraceptives and agree to remain on oral contraceptives for at least twenty-four (24) weeks after being implanted or the duration of their trial participation and agree not to become pregnant during the trial. Exclusion Criteria: * Subjects diagnosed with Type 1 Diabetes Mellitus or having a history of ketoacidosis * Subjects requiring insulin * Subjects with probable insulin production failure (fasting C Peptide serum \<1ng/mL) * Subjects that have autoimmune disease as evidenced by a positive anti-GAD blood test * Subjects with a weight loss of \> 4.5 Kg (10 lbs) within the 12 Weeks of screening * Subjects requiring prescription anticoagulation therapy * Subjects with or a history of iron deficiency and/or iron deficiency anemia * Subjects with or a history of abnormalities of the GI tract * Subjects with symptomatic gallstones or kidney stones at the time of screening * Subjects with a known infection * Subjects with or a history of coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia * Subjects mentally retarded or emotionally unstable, or exhibits psychological characteristics which, in the opinion of the Investigator, makes the Subject a poor candidate for device placement or clinical trial participation * Subjects with previous GI surgery that could affect the ability to place the device or the function of the implant * Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period * Subjects with active H. pylori (Note: Subjects may be enrolled if they had a prior history of H. Pylori and were successfully treated) * Subjects receiving weight loss medications such as Meridia, Xenical, or over the counter weight loss medications * Subject or Family history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder * Subjects with active and uncontrolled GERD * Subjects with a known history of substance abuse * Subjects participating in another ongoing investigational clinical trial * Subjects taking corticosteroids or drugs known to affect GI motility (i.e. Reglan)